Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 21, 2013; 19(31): 5138-5143
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5138
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5138
Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma
Hao Liu, Ying-Tai Chen, Yi-Bin Xie, Yan-Tao Tian, Liang-Cui, Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
Shou-Jun Yuan, De-Xuan Yang, Pharmacological and Toxicological Laboratory, Institute of Radiation Medicine Medical, Beijing 100850, China
Wei-Zhi Yang, Radiobiology Laboratory, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100021, China
Author contributions: Liu H, Yuan SJ, Yang WZ and Tian YT conceived and led the study; Liu H, Chen YT and Yang DX carried out the statistical analysis; Liu H, Chen YT, Xie YB, Cui L and Tian YT drafted and revised the manuscript; and all authors reviewed and approved the manuscript.
Correspondence to: Yan-Tao Tian, MD, Professor, Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, 17 Nan-li, Pan Jia Yuan, Chaoyang District, Beijing 100021, China. tyt67@163.com
Telephone: +86-10-87787120 Fax: +86-10-67730386
Received: May 1, 2013
Revised: June 28, 2013
Accepted: July 17, 2013
Published online: August 21, 2013
Processing time: 110 Days and 6.4 Hours
Revised: June 28, 2013
Accepted: July 17, 2013
Published online: August 21, 2013
Processing time: 110 Days and 6.4 Hours
Core Tip
Core tip: Herpes-simplex-virus encoding granulocyte-macrophage colony-stimulating factor (HSVGM-CSF) is an engineered oncolytic virus. The key features of HSVGM-CSF include the deletion of both copies of γ134.5 and the ICP47 gene as well as interruption of the ICP6 gene and insertion of the therapeutic gene GM-CSF. Our study provides the first evidence that HSVGM-CSF could inhibit the growth of pancreatic cancer in a dose-dependent manner. Enhanced GM-CSF expression might be responsible for the phenomenon.